Related Experiment Videos
Defining a renal anemia management period
1West Virginia University, Department of Medicine, Robert C. Byrd Health Science Center, Morgantown, WV 26506, USA. abesarab@hsc.wva.edu
Summary
Anemia is common in chronic renal insufficiency (CRI), often undertreated. Early treatment during the renal anemia management period (RAMP) can reduce mortality and cardiac issues.
Area of Science:
- Nephrology
- Hematology
- Cardiology
Background:
- Anemia prevalence in chronic renal insufficiency (CRI) varies by definition.
- A US dialysis patient analysis showed high rates: 67% hematocrit <30%, 51% hematocrit <28%.
- Anemia in CRI is underrecognized and undertreated despite known benefits of erythropoietin.
Purpose of the Study:
- To highlight the prevalence and impact of anemia in CRI.
- To emphasize the benefits of early anemia treatment in CRI patients.
- To introduce the concept of the renal anemia management period (RAMP).
Main Methods:
- Analysis of US dialysis patient data to estimate anemia prevalence.
- Review of existing literature on anemia treatment in CRI.
- Introduction of the RAMP concept for proactive anemia management.
Main Results:
- Anemia is highly prevalent in CRI patients, often defined by hematocrit levels.
- Anemia is a significant predictor of mortality and cardiac morbidity in CRI.
- Recombinant human erythropoietin treatment shows potential to reverse cardiac changes in CRI.
Conclusions:
- Proactive and aggressive anemia treatment during the RAMP is crucial for CRI patients.
- Early intervention can potentially prevent or reduce future morbidity associated with CRI.
- Further large-scale clinical trials are needed, but current data support early anemia management.